Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald
May 15, 2026 7:33 AM
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and {REMOVEPT} price target on Corvus Pharmaceuticals (NASDAQ: CRVS).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
